2-amino-N-phenyl-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)nicotinamide

ID: ALA4782872

PubChem CID: 162664001

Max Phase: Preclinical

Molecular Formula: C20H22N6O

Molecular Weight: 362.44

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  Nc1ncc(-c2cnn(C3CCNCC3)c2)cc1C(=O)Nc1ccccc1

Standard InChI:  InChI=1S/C20H22N6O/c21-19-18(20(27)25-16-4-2-1-3-5-16)10-14(11-23-19)15-12-24-26(13-15)17-6-8-22-9-7-17/h1-5,10-13,17,22H,6-9H2,(H2,21,23)(H,25,27)

Standard InChI Key:  YJSVSSSRRSTHBV-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
    5.9377   -1.6137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.9365   -2.4332    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6446   -2.8422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3542   -2.4328    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3514   -1.6101    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.6428   -1.2048    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.2289   -2.8386    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.4826   -2.5056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.3434   -3.8206    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.1428   -3.6512    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0626   -2.8403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0639   -3.6574    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.7722   -4.0649    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7689   -4.8795    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4764   -5.2869    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1844   -4.8771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1805   -4.0557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.4724   -3.6520    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.0576   -1.1989    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.9291   -3.1078    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.1125   -3.0192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7843   -2.2698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.9756   -2.1798    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4893   -2.8369    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.8175   -3.5863    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6321   -3.6786    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.7696   -2.4305    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  2  0
  6  1  1  0
  7  8  2  0
  8 20  1  0
  9 10  2  0
 10  7  1  0
  2  7  1  0
  4 11  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 13  1  0
  5 19  1  0
  9 20  1  0
 21 22  1  0
 21 26  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 20 21  1  0
 11 27  2  0
M  END

Alternative Forms

  1. Parent:

    ALA4782872

    ---

Associated Targets(Human)

MAP4K3 Tchem Mitogen-activated protein kinase kinase kinase kinase 3 (674 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 362.44Molecular Weight (Monoisotopic): 362.1855AlogP: 2.70#Rotatable Bonds: 4
Polar Surface Area: 97.86Molecular Species: BASEHBA: 6HBD: 3
#RO5 Violations: HBA (Lipinski): 7HBD (Lipinski): 4#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 10.12CX LogP: 1.98CX LogD: -0.63
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.66Np Likeness Score: -1.20

References

1. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC.  (2018)  Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity.,  28  (10): [PMID:29636220] [10.1016/j.bmcl.2018.03.032]

Source